Kura Oncology has formed a new subsidiary, Caspian Therapeutics, Inc., to focus on developing next-generation menin inhibitors for diabetes and other cardiometabolic diseases. Caspian has completed a $50 million Series A financing, in which Kura participated.
Key Details
- Financing: On September 8, 2026, Caspian Therapeutics completed a $50.0 million Series A private financing. Kura Oncology invested $4.3 million and now holds approximately 49.2% of Caspian's outstanding capital stock.
- Asset Contribution: Kura contributed rights to its next-generation menin inhibitors, including the compound KO-7246, and related intellectual property to Caspian in exchange for stock and up to $1.5 million in cost reimbursement.
- Operating Agreements: Kura and Caspian entered into a Contribution and License Agreement and an Intercompany Services Agreement, under which Kura will provide certain R&D and administrative services to Caspian for a fee.